Our Work

Building Your Credibility, Visibility, and Valuation all with one ultimate goal:

Making a positive impact
on human health.

Making a positive impact on human health.

We have shaped countless corporate
narratives in our more than 20-year history
at MacDougall. From debuts to IPOs to
rebrands, we’ve done it all.

We have shaped countless corporate narratives in our more than 20-year history at MacDougall. From debuts to IPOs to rebrands, we’ve done it all.

Case Study 1

our-work-case1-icon-arrow-down

show more

IPO

IPO

Situation

Vigil launched in 2020 from Atlas Venture with two ex-Amgen assets as the world’s first microglia-focused therapeutics company. By late 2021, Vigil was positioned for an IPO and worked with MacDougall, their agency of record, to develop a strategic communications plan to support their advancement to IPO.

Approach

MacDougall worked with Vigil to create strategic positioning and messaging highlighting that Vigil was the only company known to have two TREM2 modalities, representing a unique position in the neurodegenerative drug development space. In August 2021, Vigil’s Series B raise provided an opportunity for proactive media outreach to raise the company’s profile in important industry press. MacDougall also reinforced the company’s differentiated approach through all external materials including the company’s website and S-1.

Results

Vigil successfully completed a $98M IPO in January 2022 and was one of the first biotech IPOs of the year during the height of the COVID-19 pandemic. MacDougall secured industry and regional press coverage of the IPO and eventually helped orchestrate and publicize a Nasdaq Bell Ringing and related events. To date, the company has raised $313 million and now successfully operates as a NASDAQ-listed public company.

MacDougall Services: Investor Relations | Corporate Communications | Public Relations | Creative Services | Digital Services
our-work-case1-icon-arrow-up

show less

Corporate Communications

Case Study 2
our-work-case2-icon-arrow-down

show more

Corporate Communications

Situation

OcuTerra came to MacDougall with the goal of enhancing corporate visibility and amplifying the leadership team’s vision in introducing innovative treatment options for severe ophthalmic conditions. Simultaneously navigating the challenges posed by a global pandemic, the company was working to secure financing and advance a drug through clinical trials.

Approach

The first order of business was to develop strong positioning that would resonate with its key audiences, notably investors and key opinion leaders who would want to take part in the company’s clinical trials. In addition, OcuTerra needed a new website to reflect the company’s vision and mission. MacDougall took a surround sound approach, introducing key investors to OcuTerra’s leadership team, developing owned content and securing interest via targeted news media in the company’s milestones and science.

Results

MacDougall generated mass awareness for OcuTerra and executed all elements of the communications plan. We successfully generated coverage for major news milestones, developed and launched the “OcuTerra Insights” blog and unveiled creative social media campaigns. As a result, the company was invited to speak at numerous financial and industry conferences and featured on podcasts and video interviews. In addition, the CEO was named to the PharmaVoice 100, a coveted list recognizing the year’s best biotech CEOs.

MacDougall Services: Investor Relations | Corporate Communications | Public Relations | Creative Services | Digital Services

our-work-case2-icon-arrow-up

show less

Case Study 3
our-work-case3-icon-arrow-down

show more

Corporate Communications

Corporate Communications

Situation

Maravai is a leader in bioprocessing and came to MacDougall to help elevate the visibility and credibility of its executives in the space while building a narrative of Maravai’s culture of innovation. Since going public in 2020, Maravai has needed to communicate its company vision and milestones to investors and industry audiences in a way that demonstrates its value and differentiators in the market.

Approach

MacDougall took a two-pronged approach to ensure that its leaders were prepared to represent Maravai as public company spokespeople and communicate core messages to key audiences. MacDougall conducted an in-person messaging workshop followed by a spokesperson training session focused on public company guardrails, best practices for media & investors, interactive case studies, scenarios, mock Q&As and more. Additionally, MacDougall interviewed five Maravai executives and created an award and thought leadership strategy to spotlight Maravai’s excellence in innovation and outstanding executive contributions.

Results

MacDougall has guided Maravai’s executive team through multiple high touchpoint events with key audiences, including an Investor R&D Day, investor tours, media articles and speaking engagements at industry conferences. Additionally, the teams worked together to updated executive bios, recorded a forthcoming podcast, and secured numerous award wins in 2023 (71% success rate), including PharmaVoice 100 list of change agents, San Diego Business Journal’s Leaders of Influence in Life Sciences and 2023 by R&D World Magazine’s 100 revolutionary technologies.
MacDougall Services: Investor Relations | Corporate Communications | Public Relations | Creative Services | Digital Services
our-work-case3-icon-arrow-up

show less

Want to see more examples? Click here to download a few more. Or even better, contact us and let us answer your questions directly. We’d love the opportunity to learn more about your needs and talk about solutions.

Explore

We are determined, results-driven, unflappable, curious, creative and principled.